Multicenter Study From 22 Expert Centers
OBJECTIVE: This study aimed to identify benchmark values for robotic right hepatectomy (RH) based on a low-risk cohort treated at expert centers. BACKGROUND: Robotic liver surgery is emerging as a preferred minimally invasive approach to the liver. To enable conclusive comparisons with the standard open or laparoscopic approaches, reference values are needed. METHODS: Outcomes from consecutive patients undergoing robotic RH for malignant or benign indications at 22 international expert centers between 2018 and 2024 were analyzed. Low-risk, benchmark patients were without significant comorbidities such as portal hypertension, Child B cirrhosis, cardiac disease, chronic pulmonary disease, and renal failure. Patients undergoing robotic RH for donor hepatectomy were excluded. Fifteen reference values were derived from the 75th or the 25th percentile of the median values of all centers. Reference values were compared with a laparoscopic cohort from 4 centers and published benchmark values for laparoscopic and open RH. RESULTS: Of 357 patients, 172 (48%) qualified as the benchmark cohort. The main indications were hepatocellular carcinoma (31%) and colorectal liver metastases (27%). Reference values included: operative time (≤476 min), conversion rate (≤8.2%), bile leak (≤15.4%), major complications (≤23.1%), and comprehensive complication index at 90 days (≤15.6). Robotic RH compared favorably to a multinational cohort series of laparoscopic RH with lower conversion (10.0% vs ≤8.2%) and R1 rate (10.9% vs ≤0%). Compared to open robotic hepatectomy, cutoffs for major complications (≤50.0% vs ≤23.1%) and liver failure (≤22.0% vs ≤2.7%) were lower for robotic right hepatectomies. CONCLUSION: This international benchmark study on robotic right hepatectomy (RRH) demonstrates that the robotic approach provides advantages compared with laparoscopic and open RH. RRH can be expected to become the minimally invasive approach of choice for tumors in the right liver.
Authors
- Mirhasan Rahimli (ORCID: https://orcid.org/0000-0002-6708-6596)
- John B. Martinie (ORCID: https://orcid.org/0000-0002-2677-9134)
- Philipp H. von Kroge (ORCID: https://orcid.org/0000-0003-2971-8537)
- Janina Eden (ORCID: https://orcid.org/0000-0002-8724-9313)
- S Katou
- Gi Hong Choi (ORCID: https://orcid.org/0000-0002-1593-3773)
- Christian Toso (ORCID: https://orcid.org/0000-0003-1652-4522)
- Jason Hawksworth
- Asmus Heumann (ORCID: https://orcid.org/0009-0001-5542-579X)
- Leonardo Centonze
- Juba Ait Mohand
- Roberta Odorizzi
- Sarkis Drejian
- Bjørn E. Edwin
- Cristiano Guidetti
- Mohammed Abu Hilal
- Andreas Pascher (ORCID: https://orcid.org/0000-0002-0358-7586)
- Beat Moeckli
- Schaima Abdelhadi (ORCID: https://orcid.org/0009-0001-7332-9240)
- Christoph Tschuor
- Simon Störzer
- Michael Ginesini
- Rutger-Jan Swijnenburg
- Roberto Ivan Troisi
- Hugo Pinto Marques
- Raphael L. C. Araujo
- Beat P. Müller
- Daisuke Fukumori
- Noa L. E. Aegerter
- Florian Primavesi
- Mafalda Sobral
- Yuta Abe
- Gabriela Pilz da Cunha
- Gianluca Rompianesi
- Go Wakabayashi
- Victor Lopez-Lopez
- Benjamin Struecker
- Fabrizio Di Benedetto
- Tomoaki Kato
- Andrea Lauterio
- Philip C Müller
- Ricardo Robles-Campos
- Mickaël Lesurtel
- Taiga Wakabayashi
- Yutaka Nakano
- Stefan Stättner
- Roland Croner
- Zhihao Li
- Iswanto Sucandy
- Moritz Schmelzle
- Charles Chung-Wei Lin
- Antonella Delvecchio
- Soufyan El Adel
- Ugo Boggi
- Christoph Reissfelder
- Adrian T Billeter
- Riccardo Memeo
- Philipp Dutkowski
- Christoph Kuemmerli
Publication Details
- Journal
- Portuguese National Funding Agency for Science, Research and Technology (RCAAP Project by FCT)
- Published
- 2025-12-01
- Primary Topic
- Hepatocellular Carcinoma Treatment and Prognosis
- Type
- article
- Field-Weighted Citation Impact
- 0.00